Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

IMPT-514

Cell therapy (CAR-T) · Kills target cells · developed by Lyell Immunopharma

Phase 1/2 Most advanced trial (none active)

LYEL Developer

1 Registered trials

What is IMPT-514?

IMPT-514 is a CAR T-cell therapy administered intravenously after lymphodepleting chemotherapy with fludarabine and cyclophosphamide. It is being studied in systemic lupus erythematosus and lupus nephritis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Cell therapy (CAR-T)
Mechanism: Kills target cells
Therapy area: Immunology
Developer: Lyell Immunopharma, Inc. (LYEL)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06153095	Phase 1/2	Systemic Lupus Erythematosus	Withdrawn	LYEL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Lupus NephritisSystemic Lupus Erythematosus

More from Lyell Immunopharma

LYL273 Phase 1/2 LYL797 Phase 1 LYL845 Phase 1 Rondecabtagene Autoleucel Phase 3

Sources

ClinicalTrials.gov NCT06153095

Updated Oct 3, 2026. Something wrong or missing? Report it on the LYEL page.

Follow LYEL, the company behind IMPT-514

See LYEL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LYEL catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z